Tofacitinib-treated and R406-treated ADSC adipocytes showed increased basal lipolysis, but no significant increase in forskolin-stimulated lipolysis. Tofacitinib inhibited pSTAT3 and pSTAT1 expression in PsAFLS compared with vehicle control. In mouse adipose explants cultured in adipogenic medium, Tofacitinib increased UCP1 expression in subcutaneous explants, but not visceral explants, compared with DMSO. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Basal and stimulated lipolysis in adipocytes
Cell-based study · ADSC adipocytes [1]
Tofacitinib-treated and R406-treated ADSC adipocytes showed increased basal lipolysis, assessed by glycerol release, but no significant increase in forskolin-stimulated lipolysis.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2 μM
- Exposure duration
- starved in DMEM containing 1% FBS for 1 h
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Tofacitinib
The paper names Tofacitinib without stating the salt or form; not verified as the citrate form supplied as A10241. No dose conversion or lot validation.
RESULTS > JAK-inactivated adipocytes acquire a brown-like metabolic program (S75); METHODS > Browning assay with tofacitinib, R406, JAK inhibitors and BMP7 (S151); METHODS > Lipolysis assay (S188); Figure 6 legend (S284, S285)
quantification of glycerol release: quantification of glycerol release; comparator: DMSO — RESULTS > JAK-inactivated adipocytes acquire a brown-like metabolic program (S75); Figure 6 legend (S284)
Tofacitinib inhibits pSTAT expression in PsAFLS
Cell-based study · PsAFLS (n=7) [2]
PsAFLS were treated with Tofacitinib and compared with vehicle control. Tofacitinib inhibited pSTAT3 and pSTAT1 expression.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µM
- Exposure duration
- 24 h
- Vehicle
- dimethyl sulfoxide (DMSO)
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Tofacitinib
The paper names Tofacitinib without stating the salt or form; not verified as the citrate form supplied as A10241. No dose conversion or lot validation.
Results > Tofacitinib regulates STAT signalling in primary PsAFLS (S15); Figure 1 legend (S33, S34)
Densitometry quantification of pSTAT3/pSTAT1: Densitometry quantification of pSTAT3/pSTAT1; comparator: vehicle control — Results > Tofacitinib regulates STAT signalling in primary PsAFLS (S15); Figure 1 legend (S34)
Depot-specific UCP1 expression in adipose explants
Cell-based study · Subcutaneous and visceral adipose depots were dissected from 8 week old male C57/Bl6 mice (n=5) [1]
In adipose explants from male mice cultured in adipogenic medium, Tofacitinib increased UCP1 expression in subcutaneous explants, but not visceral explants, compared with DMSO.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 2 and 5 μM
- Exposure duration
- Media with fresh compound was replaced every other day. Following 7 days of treatments
- Method
- adipogenic medium containing DMSO, tofacitinib or R406
- Co-treatment
- Other interventions in this design: insulin 17 nM; dexamethasone 1 μM. Compound effect isolated by the comparison: DMSO, tofacitinib or R406.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Tofacitinib
The paper names Tofacitinib without stating the salt or form; not verified as the citrate form supplied as A10241. No dose conversion or lot validation.
RESULTS > Validation of tofacitinib and R406 browning compounds in primary adipocytes (S32); METHODS > Browning of mouse adipose tissue explants (S157, S160, S162, S163)
UCP1 expression: UCP1 expression; comparator: DMSO — RESULTS > Validation of tofacitinib and R406 browning compounds in primary adipocytes (S32)